Idinvest Partners

Kurma Partners and fellow seed investors have gained an early exit via the acquisition of Corlieve Therapeutics S.A.S. by uniQure N.V. (NASDAQ:QURE) for €46.3 million ($55.1 million) up front

IO Biotech parlayed early clinical data into a €127 million ($154.8 million) series B financing led by HBM Healthcare Investments, which will support a Phase II trial of its leading cancer

Kurma is the latest European life sciences VC to raise a record fund

ImCheck’s $53M series B will bring at least one T cell-activating antibody to the clinic, broaden immuno-oncology pipeline

French VC’s company creation office in Munich yields first start-up, a Max Planck Institute spinout

How DNA Script plans to help researchers speed R&D with its enzymatic DNA synthesis technology